Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
WASHINGTON, Feb. 4, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its…
Comments Off on Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis